Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.69 |
| ▸ | CA1 | P00915 | 4/20 | 0.69 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.49 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7559158 | 1.00 | CA2 (0.69) | CA2CA1CPB2GSRMAPK1 | |
| SCHEMBL7852802 | 0.93 | CA2 (0.72) | CA2CA1CPB2GSRMAPK1 | |
| SCHEMBL277393 | 0.84 | CA2 (0.87) | CA2CA1MAPK1 | |
| SCHEMBL7748769 | 0.84 | — | — | |
| SCHEMBL29479266 | 0.83 | CA2 (0.64) | CA2CA1CPB2MAPK1GNAI3 | |
| SCHEMBL24635138 | 0.83 | CA2 (0.69) | CA2CA1MAPK1 | |
| SCHEMBL3628614 | 0.83 | CA2 (0.83) | CA2CA1MAPK1 | |
| SCHEMBL3859929 | 0.83 | CA2 (0.83) | CA2CA1MAPK1 | |
| Hydrochloric Acid SCHEMBL8533142 | 0.83 | CA2 (0.83) | CA2CA1MAPK1 | |
| SCHEMBL1668977 | 0.83 | CA2 (0.83) | CA2CA1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | Epizyme, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20120165275-A1 | Nitrogen-Based Linkers for Attaching Modifying Groups to Polypeptides and Other Macromolecules | AFFYMAX, INC. (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165275-A1 | Nitrogen-Based Linkers for Attaching Modifying Groups to Polypeptides and Other Macromolecules | DNPEP, NGLY1, LNPEP | CA2 4362/4885CA1 1155/4885CPB2 1075/4885 |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | SMYD3, SMYD2, SNRPD3 | CA2 1680/4885CA1 3908/4885CPB2 4469/4885 |
| US-20170355695-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | CA2 1550/4885CA1 3738/4885CPB2 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.